VANCOUVER, March 10, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced that effective at the opening of trading on Monday, March 13, 2017, shares of Neovasc will commence trading on the Toronto Stock Exchange ("TSX") under the symbol NVCN.
Following this change, the Company's TSX and Nasdaq Stock Market symbols will be the same. No action is required to be taken by current shareholders in connection with the change.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™, for the treatment of refractory angina which is not currently available in the U.S. and has been available in Europe since 2015 and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under investigation in the U.S., Canada and Europe. The Company also sells a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves. For more information, visit: www.neovasc.com.
SOURCE Neovasc Inc.